Bio-Rad Laboratories, Inc. BIO.B Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Clinical Diagnostics | $1.57B+2.8% | $1.56B+1.6% | $1.53B-0.3% | $1.53B+0.9% | $1.53B+1.3% | |
| Life Science | $1.02B+0.6% | $1.02B-0.7% | $1.03B-1.5% | $1.03B-1.9% | $1.02B-7.4% | |
| Gross Profit by Business | ||||||
| Clinical Diagnostics | $791M+1.4% | $786.8M-1.2% | $757.8M-5.5% | $766.3M-2.6% | $779.8M+1.7% | |
| Life Science | $552.3M-4.6% | $553.1M-5.0% | $578.8M-2.3% | $582.8M-4.2% | $579.1M-8.0% | |
| Total Assets by Business | ||||||
| Clinical Diagnostics | $1.88B-3.5% | $1.89B-3.3% | $1.92B-3.2% | $1.94B— | $1.95B— | |
| Life Science | $1.21B+0.3% | $1.22B+2.2% | $1.22B+2.0% | $1.21B— | $1.21B— | |
| Cost of goods sold by Business | ||||||
| Clinical Diagnostics | $777.9M+4.2% | $775.3M+4.6% | $771.5M+7.7% | $760.6M+6.4% | $746.3M+3.8% | |
| Life Science | $468.7M+7.5% | $468M+5.0% | $449.4M-1.3% | $444.5M-6.0% | $435.9M-12.1% | |
| Depreciation, Depletion and Amortization by Business | ||||||
| Clinical Diagnostics | $91.9M+8.8% | $90.4M+7.4% | $89.3M+7.4% | $87.2M+5.8% | $84.5M+1.7% | |
| Life Science | $76.3M+12.0% | $75M+11.3% | $72.8M+10.8% | $69.6M+8.8% | $68.1M+7.4% | |
| Goodwill by Business | ||||||
| Clinical Diagnostics | $1.69B+1.6% | $1.68B+1.4% | $1.67B+0.6% | $1.67B+0.9% | $1.66B+0.4% | |
| Life Science | $1.97B+47.9% | $1.81B+36.1% | $1.65B+24.1% | $1.5B+12.1% | $1.33B0.0% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Clinical Diagnostics | $6M+233% | $10.1M+426% | $4.6M-43.2% | $7.6M— | $1.8M— | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Clinical Diagnostics | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | |
| Life Science | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | |
| Goodwill, net by Business | ||||||
| Clinical Diagnostics | $512.5M+5.4% | $507.2M+4.7% | $497.8M+2.1% | $493.9M+3.0% | $486.3M+1.5% | |
| Life Science | $1.8B+54.8% | $1.65B+41.3% | $1.49B+27.6% | $1.33B+13.9% | $1.17B0.0% | |
| Goodwill, Period Increase (Decrease) by Business | ||||||
| Clinical Diagnostics | $6M+233% | $10.1M+426% | $4.6M-43.2% | $7.6M— | $1.8M— | |
| Life Science | $159.4M— | $162.1M— | $161.9M— | $161.9M— | $0— | |
| Net Sales by Geography | ||||||
| Americas | $170.7M+1.2% | $165.4M-2.3% | $162M-5.4% | $163.1M-6.8% | $168.6M+0.6% | |
| Asia Pacific | $519.6M+2.2% | $513.3M-1.6% | $497.9M-7.7% | $503.8M-5.2% | $508.6M-6.4% | |
| Europe | $888.8M+6.6% | $881.8M+5.7% | $860.9M+4.6% | $844.4M+4.2% | $833.7M+2.3% | |
| UNITED STATES | $1.01B-1.9% | $1.02B-1.8% | $1.04B-0.9% | $1.04B-0.3% | $1.03B-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Rad Laboratories, Inc. break its business down?
- Bio-Rad Laboratories, Inc. (BIO.B) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Rad Laboratories, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
